211 related articles for article (PubMed ID: 34583939)
1. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
[TBL] [Abstract][Full Text] [Related]
2. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
3. Manipulating regulatory T cells: a promising strategy to treat autoimmunity.
Zhang D; Tu E; Kasagi S; Zanvit P; Chen Q; Chen W
Immunotherapy; 2015; 7(11):1201-11. PubMed ID: 26568117
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
5. Treatment With FoxP3+ Antigen-Experienced T Regulatory Cells Arrests Progressive Retinal Damage in a Spontaneous Model of Uveitis.
Liu YH; Mölzer C; Makinen K; Kamoi K; Corbett CLC; Klaska IP; Reid DM; Wilson HM; Kuffová L; Cornall RJ; Forrester JV
Front Immunol; 2020; 11():2071. PubMed ID: 33013877
[TBL] [Abstract][Full Text] [Related]
6. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
7. Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination
DeOca KB; Moorman CD; Garcia BL; Mannie MD
Front Immunol; 2020; 11():541619. PubMed ID: 33072087
[TBL] [Abstract][Full Text] [Related]
8. Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.
Selck C; Dominguez-Villar M
Front Immunol; 2021; 12():661875. PubMed ID: 34054826
[TBL] [Abstract][Full Text] [Related]
9. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.
Khoryati L; Pham MN; Sherve M; Kumari S; Cook K; Pearson J; Bogdani M; Campbell DJ; Gavin MA
Sci Immunol; 2020 Aug; 5(50):. PubMed ID: 32817295
[TBL] [Abstract][Full Text] [Related]
10. B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitis.
Sun JB; Czerkinsky C; Holmgren J
J Immunol; 2012 Feb; 188(4):1686-97. PubMed ID: 22250081
[TBL] [Abstract][Full Text] [Related]
11. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit.
Sun JB; Flach CF; Czerkinsky C; Holmgren J
J Immunol; 2008 Dec; 181(12):8278-87. PubMed ID: 19050244
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
13. Treg Enhancing Therapies to Treat Autoimmune Diseases.
Eggenhuizen PJ; Ng BH; Ooi JD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
[TBL] [Abstract][Full Text] [Related]
14. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
Front Immunol; 2022; 13():974188. PubMed ID: 36059465
[TBL] [Abstract][Full Text] [Related]
15. The role of FOXP3
Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
[TBL] [Abstract][Full Text] [Related]
16. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy.
Boonpiyathad T; Sokolowska M; Morita H; Rückert B; Kast JI; Wawrzyniak M; Sangasapaviliya A; Pradubpongsa P; Fuengthong R; Thantiworasit P; Sirivichayakul S; Kwok WW; Ruxrungtham K; Akdis M; Akdis CA
Allergy; 2019 May; 74(5):976-985. PubMed ID: 30485456
[TBL] [Abstract][Full Text] [Related]
17. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
Terry LV; Oo YH
Front Immunol; 2020; 11():565518. PubMed ID: 33072105
[TBL] [Abstract][Full Text] [Related]
18. CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection.
Jiang S; Lechler RI
Inflamm Allergy Drug Targets; 2006 Dec; 5(4):239-42. PubMed ID: 17168794
[TBL] [Abstract][Full Text] [Related]
19. Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation.
Landman S; de Oliveira VL; Peppelman M; Fasse E; van Rijssen E; Bauland SC; van Erp P; Joosten I; Koenen HJPM
J Immunol Res; 2020; 2020():7680131. PubMed ID: 32509883
[TBL] [Abstract][Full Text] [Related]
20. Treg Therapies Revisited: Tolerance Beyond Deletion.
Pilat N; Sprent J
Front Immunol; 2020; 11():622810. PubMed ID: 33633742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
